OBJECTIVE: In February 2008, we alerted the Advisory Committee on Immunization Practices to preliminary evidence of a twofold increased risk of febrile seizures after the combination measles-mumps-rubella-varicella (MMRV) vaccine when compared with separate measles-mumps-rubella (MMR) and varicella vaccines. Now with data on twice as many vaccine recipients, our goal was to reexamine seizure risk after MMRV vaccine. METHODS: Using 2000-2008 Vaccine Safety Datalink data, we assessed seizures and fever visits among children aged 12 to 23 months after MMRV and separate MMR + varicella vaccines. We compared seizure risk after MMRV vaccine to that after MMR + varicella vaccines by using Poisson regression as well as with supplementary regressions that incorporated chart-review results and self-controlled analyses. RESULTS: MMRV vaccine recipients (83,107) were compared with recipients of MMR + varicella vaccines (376,354). Seizure and fever significantly clustered 7 to 10 days after vaccination with all measles-containing vaccines but not after varicella vaccination alone. Seizure risk during days 7 to 10 was higher after MMRV than after MMR + varicella vaccination (relative risk: 1.98 [95% confidence interval: 1.43-2.73]). Supplementary analyses yielded similar results. The excess risk for febrile seizures 7 to 10 days after MMRV compared with separate MMR + varicella vaccination was 4.3 per 10,000 doses (95% confidence interval: 2.6-5.6). CONCLUSIONS: Among 12- to 23-month-olds who received their first dose of measles-containing vaccine, fever and seizure were elevated 7 to 10 days after vaccination. Vaccination with MMRV results in 1 additional febrile seizure for every 2300 doses given instead of separate MMR + varicella vaccines. Providers who recommend MMRV should communicate to parents that it increases the risk of fever and seizure over that already associated with measles-containing vaccines.
OBJECTIVE: In February 2008, we alerted the Advisory Committee on Immunization Practices to preliminary evidence of a twofold increased risk of febrile seizures after the combination measles-mumps-rubella-varicella (MMRV) vaccine when compared with separate measles-mumps-rubella (MMR) and varicella vaccines. Now with data on twice as many vaccine recipients, our goal was to reexamine seizure risk after MMRV vaccine. METHODS: Using 2000-2008 Vaccine Safety Datalink data, we assessed seizures and fever visits among children aged 12 to 23 months after MMRV and separate MMR + varicella vaccines. We compared seizure risk after MMRV vaccine to that after MMR + varicella vaccines by using Poisson regression as well as with supplementary regressions that incorporated chart-review results and self-controlled analyses. RESULTS: MMRV vaccine recipients (83,107) were compared with recipients of MMR + varicella vaccines (376,354). Seizure and fever significantly clustered 7 to 10 days after vaccination with all measles-containing vaccines but not after varicella vaccination alone. Seizure risk during days 7 to 10 was higher after MMRV than after MMR + varicella vaccination (relative risk: 1.98 [95% confidence interval: 1.43-2.73]). Supplementary analyses yielded similar results. The excess risk for febrile seizures 7 to 10 days after MMRV compared with separate MMR + varicella vaccination was 4.3 per 10,000 doses (95% confidence interval: 2.6-5.6). CONCLUSIONS: Among 12- to 23-month-olds who received their first dose of measles-containing vaccine, fever and seizure were elevated 7 to 10 days after vaccination. Vaccination with MMRV results in 1 additional febrile seizure for every 2300 doses given instead of separate MMR + varicella vaccines. Providers who recommend MMRV should communicate to parents that it increases the risk of fever and seizure over that already associated with measles-containing vaccines.
Authors: Sharon K Greene; Melisa Rett; Eric S Weintraub; Lingling Li; Ruihua Yin; Anthony A Amato; Doreen T Ho; Sarah I Sheikh; Bruce H Fireman; Matthew F Daley; Edward A Belongia; Steven J Jacobsen; Roger Baxter; Tracy A Lieu; Martin Kulldorff; Claudia Vellozzi; Grace M Lee Journal: Am J Epidemiol Date: 2012-05-11 Impact factor: 4.897
Authors: Lakshmi Sukumaran; Michael M McNeil; Pedro L Moro; Paige W Lewis; Scott K Winiecki; Tom T Shimabukuro Journal: Clin Infect Dis Date: 2015-01-30 Impact factor: 9.079
Authors: Sean T O'Leary; Mandy A Allison; Shannon Stokley; Lori A Crane; Laura P Hurley; Brenda Beaty; Allison Kempe Journal: Prev Med Date: 2013-01-15 Impact factor: 4.018
Authors: Kristine Macartney; Heather F Gidding; Lieu Trinh; Han Wang; Aditi Dey; Brynley Hull; Karen Orr; Jocelynne McRae; Peter Richmond; Michael Gold; Nigel Crawford; Jennifer A Kynaston; Peter McIntyre; Nicholas Wood Journal: JAMA Pediatr Date: 2017-10-01 Impact factor: 16.193
Authors: Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Nathaniel D Lambert; V Shane Pankratz; Gregory A Poland Journal: Hum Genet Date: 2014-08-07 Impact factor: 4.132